Literature DB >> 9831815

Apolipoprotein E polymorphism in elderly Chilean people with Alzheimer's disease.

P Quiroga1, C Calvo, C Albala, J Urquidi, J L Santos, H Pérez, G Klaassen.   

Abstract

As a part of the WHO Age-Associated Dementia Project, Chile has been participating in a cross-national survey on dementia frequency and determinants since 1989. In the present study, apolipoprotein E (ApoE) polymorphism genotypes have been compared in 95 patients with Alzheimer's disease (AD) (mean age 80.7; 95% CI 79.2-82.2, range 66-97) and 187 healthy people (mean age 78.2; 95% CI 77.2-79.2, range 65-93). Isoelectric focusing and immunoblotting with anti-human ApoE polyclonal antibody were used to determine the distribution of ApoE genotypes. Dementia was diagnosed according to DSM-III-R and ICD-10 clinical criteria. The diagnosis of probable or possible AD was made according to the NINCDS-ADRDA criteria. The ApoE allele frequencies in healthy people were calculated to be epsilon2 = 0.07, epsilon3 = 0.74 and epsilon4 = 0.19. In the probable AD disease group, the frequencies were epsilon2 = 0.08, epsilon3 = 0.52 and epsilon4 = 0.40. The odds ratio (OR) for epsilon4 carriers compared with non-epsilon4 carriers was estimated to be 2.9 (95% CI 1.7-5.1). Taking the genotype epsilon3/epsilon3 as the reference group, the OR for the epsilon4/epsilon4 genotype was estimated to be 12.8 (95% CI 3.9-47.6) and for epsilon3/epsilon4 subjects it was 2.4 (1.3-4.5). These results support the association between ApoE epsilon4 allele with late-onset AD in a Chilean population.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9831815     DOI: 10.1159/000026195

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  6 in total

Review 1.  Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence.

Authors:  Yu Yamazaki; Meghan M Painter; Guojun Bu; Takahisa Kanekiyo
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

Review 2.  Exercise, APOE genotype, and the evolution of the human lifespan.

Authors:  David A Raichlen; Gene E Alexander
Journal:  Trends Neurosci       Date:  2014-03-30       Impact factor: 13.837

Review 3.  Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors.

Authors:  Raj N Kalaria; Gladys E Maestre; Raul Arizaga; Robert P Friedland; Doug Galasko; Kathleen Hall; José A Luchsinger; Adesola Ogunniyi; Elaine K Perry; Felix Potocnik; Martin Prince; Robert Stewart; Anders Wimo; Zhen-Xin Zhang; Piero Antuono
Journal:  Lancet Neurol       Date:  2008-07-28       Impact factor: 44.182

Review 4.  Factors Influencing Alzheimer's Disease Risk: Whether and How They are Related to the APOE Genotype.

Authors:  Rong Zhang; Xiaojiao Xu; Hang Yu; Xiaolan Xu; Manli Wang; Weidong Le
Journal:  Neurosci Bull       Date:  2022-02-11       Impact factor: 5.271

5.  Association between the APOE ε4 Allele and Late-Onset Alzheimer's Disease in an Ecuadorian Mestizo Population.

Authors:  Stefany Montufar; Cristian Calero; Rodrigo Vinueza; Patricio Correa; Andrea Carrera-Gonzalez; Franklin Villegas; Germania Moreta; Rosario Paredes
Journal:  Int J Alzheimers Dis       Date:  2017-12-04

Review 6.  Alzheimer's Disease: From Genetic Variants to the Distinct Pathological Mechanisms.

Authors:  Qiying Sun; Nina Xie; Beisha Tang; Rena Li; Yong Shen
Journal:  Front Mol Neurosci       Date:  2017-10-06       Impact factor: 5.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.